Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.26 USD | +2.91% | -2.42% | -3.71% |
Jul. 01 | IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell Small Cap Comp Value Index | CI |
Jul. 01 | IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Growth Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.71% | 2.52B | D+ | ||
+18.97% | 44.44B | B- | ||
+41.98% | 40.03B | A | ||
-10.06% | 37.68B | B | ||
+31.15% | 31.46B | B | ||
-7.79% | 27.29B | C | ||
+13.32% | 26.29B | B- | ||
+43.05% | 13.8B | B+ | ||
+31.28% | 12.46B | C+ | ||
-7.41% | 11.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IDYA Stock
- Ratings IDEAYA Biosciences, Inc.